v3.26.3
Revenue
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net product revenue$22,650 $16,331 $62,506 $42,658 
Collaboration and other revenue
1,747 1,270 4,664 3,229 
Revenue$24,397 $17,601 $67,170 $45,887 
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront, and milestone payments we receive under these types of contracts. See Note 3 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue resulting from our collaboration with Boehringer Ingelheim, as well as the sale of product rights. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were 2 percent of U.S. revenue during the three and nine months ended September 30, 2026 and less than 1 percent of U.S. revenue during the three and nine months ended September 30, 2025.
Disaggregation of Revenue
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended September 30, 2026 and 2025:
Three Months Ended September 30,
20262025
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Cardiometabolic Health:
Mounjaro$4,998 $5,725 $10,723 $3,550 $2,965 $6,515 
Zepbound(1)
5,267 86 5,352 3,568 20 3,588 
Jardiance(2)
781 796 1,578 424 535 959 
Trulicity601 302 904 707 345 1,052 
Other cardiometabolic health729 479 1,207 618 446 1,064 
Total cardiometabolic health12,376 7,388 19,764 8,867 4,311 13,178 
Oncology:
Verzenio897 614 1,511 880 590 1,470 
Other oncology621 468 1,089 495 443 937 
Total oncology1,518 1,082 2,600 1,375 1,033 2,408 
Immunology:
Taltz539 316 856 583 318 902 
Other immunology262 318 579 190 271 461 
Total immunology801 634 1,435 773 589 1,362 
Neuroscience384 59 444 240 76 316 
Other
57 97 154 45 292 337 
Revenue$15,136 $9,261 $24,397 $11,300 $6,301 $17,601 
(1) Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the U.S.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the nine months ended September 30, 2026 and 2025:
Nine Months Ended September 30,
20262025
U.S.Outside U.S.TotalU.S.Outside U.S.Total
Cardiometabolic Health:
Mounjaro$14,022 $15,306 $29,328 $9,508 $6,048 $15,556 
Zepbound(1)
14,273 167 14,440 9,254 28 9,281 
Jardiance(2)
1,909 2,014 3,924 1,116 1,547 2,663 
Trulicity2,109 932 3,042 2,221 1,018 3,239 
Other cardiometabolic health1,728 1,416 3,143 1,709 1,281 2,989 
Total cardiometabolic health34,041 19,836 53,877 23,807 9,922 33,729 
Oncology:
Verzenio2,448 1,838 4,286 2,467 1,651 4,118 
Other oncology1,770 1,381 3,151 1,373 1,277 2,650 
Total oncology4,218 3,219 7,437 3,840 2,929 6,769 
Immunology:
Taltz1,495 949 2,444 1,609 902 2,511 
Other immunology716 895 1,611 444 751 1,195 
Total immunology2,211 1,844 4,055 2,052 1,654 3,706 
Neuroscience1,002 253 1,254 677 255 932 
Other197 349 546 227 525 752 
Revenue$41,668 $25,502 $67,170 $30,604 $15,283 $45,887 
(1) Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the U.S.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
The following table summarizes revenue by geographical area:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue(1):
U.S.$15,136 $11,300 $41,668 $30,604 
Europe4,459 3,498 12,219 8,461 
China947 560 2,582 1,477 
Japan648 555 1,847 1,478 
Rest of world3,206 1,688 8,854 3,867 
Revenue$24,397 $17,601 $67,170 $45,887 
(1) Revenue is attributed to the countries based on the location of the customer or other party.